BCR-ABL tyrosine kinase inhibitors
Bosutinib
The FDA lists this product in 6 strengths and forms.
Composition
- Active ingredients
- BOSUTINIB MONOHYDRATE EQ 100MG BASE
Strengths and forms
The FDA lists each strength of a product separately; these pages share one label.
- BOSUTINIB MONOHYDRATE EQ 100MG BASE · TabletThis page
- BOSUTINIB MONOHYDRATE EQ 500MG BASE · TabletANDA209624-003 · Tentative approval
- BOSUTINIB MONOHYDRATE 400MG · TabletANDA209624-001 · Tentative approval
- BOSUTINIB MONOHYDRATE EQ 100MG BASE · TabletANDA209577-002 · Tentative approval
- BOSUTINIB MONOHYDRATE EQ 500MG BASE · TabletANDA209577-003 · Tentative approval
- BOSUTINIB MONOHYDRATE 400MG · TabletANDA209577-001 · Tentative approval
Official product information
Drugs@FDA lists the approved labels, letters and reviews for application ANDA209624.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.